Literature DB >> 19765432

Cadaveric renal transplantation: a single-center experience.

A Ghafari1, A Taghizade Afshari, Kh Makhdoomi, N Sepehrvand, M Gasemi-Rad, S Z Shamspour, N Maleki, T Abbasi.   

Abstract

INTRODUCTION: Renal transplantation remains the treatment of choice for end-stage renal disease (ESRD) in regard to patient survival. Iran was one of the first countries in the Middle East that began renal transplantation.
METHODS: In a follow-up study, we enrolled all of our cadaveric renal transplant recipients from 2001 to 2007, namely, 39 cases. Related variables collected through checklists were entered into SPSS software version 16 and analyzed using the Kaplan-Meier method and by descriptive statistics.
RESULTS: The mean age of the recipients was 35.18 +/- 14.27 years. Twenty-one patients (53.8%) were men. The underlying disease for development of ESRD was diabetes (7 cases, 21.2%), hypertension (24.2%), glomerulopathies (36.4%), polycystic disease (PKD; 2.6%), and 5 (15.2%) were unknown. Four recipients (10.3%) were hospitalized again because of acute tubular necrosis after transplantation. An acute rejection episode was diagnosed in 7 (17.9%) graft recipients. Surgical complications after transplantation were as follows: urinoma, lymphocele, and surgical site leakage (each 1 case). One-year patient survival rate was 89.7% in this study; 4 recipients died within 1-9 months after transplantation. Death-censored 1-year graft survival rate was 100%. DISCUSSION: The survival rate of cadaveric transplant was in an acceptable range.

Entities:  

Mesh:

Year:  2009        PMID: 19765432     DOI: 10.1016/j.transproceed.2009.07.005

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  1 in total

1.  Cadaveric renal transplantation: Our experience at a tertiary care centre in India.

Authors:  Debabrata Mukherjee; Ranjith K Nair; Sourabh Sharma; Bhaskar Datt; Ananth Rao; Sudeep Prakash
Journal:  Med J Armed Forces India       Date:  2018-11-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.